Quick Answer
ANAPTYSBIO, INC reported Cash and Equivalents of $238.20 million for fiscal year 2025.
ANAPTYSBIO, INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $238.20M | +93.5% |
| 2024 | $123.08M | +242.2% |
| 2023 | $35.97M | -49.6% |
| 2022 | $71.31M | -85.6% |
| 2021 | $495.73M | +97.9% |
| 2020 | $250.46M | +46.5% |
| 2019 | $171.02M | +50.5% |
| 2018 | $113.60M | +39.9% |
| 2017 | $81.19M | +58.5% |
| 2016 | $51.23M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $109.83M | -42.7% | +147.9% |
| June 30, 2025 | $44.30M | -38.3% | -55.1% |
| March 31, 2025 | $98.64M | +83.7% | -19.9% |
| December 31, 2024 | $123.08M | +242.2% | -35.8% |
| September 30, 2024 | $191.58M | +628.6% | +166.7% |
| June 30, 2024 | $71.82M | +104.0% | +33.8% |
| March 31, 2024 | $53.70M | -43.2% | +49.3% |
| December 31, 2023 | $35.97M | -49.6% | +36.8% |
- ANAPTYSBIO, INC showed an increase of +93.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2025 period, ANAPTYSBIO, INC’s cash and equivalents has grown by 364.9% (from $51.23 million to $238.20 million).
- The most recent figure is from ANAPTYSBIO, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: